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Abstract: Depression and cognitive impairment are intimately associated, especially in elderly people.
However, the association between late-life depression (LLD) and mild cognitive impairment (MCI) is
complex and currently unclear. In general, it can be said that LLD and cognitive impairment can be
due to a common cause, such as a vascular disease, or simply co-exist in time but have different causes.
To contribute to the understanding of the evolution and prognosis of these two diseases, this study’s
primary intent was to explore the ability of artificial neural networks (ANNs) to identify an MCI
subtype associated with depression as an entity by using the scores of an extensive neurological
examination. The sample consisted of 96 patients classified into two groups: 42 MCI with depression
and 54 MCI without depression. According to our results, ANNs can identify an MCI that is highly
associated with depression distinguishable from the non-depressed MCI patients (accuracy = 86%,
sensitivity = 82%, specificity = 89%). These results provide data in favor of a cognitive frontal profile
of patients with LLD, distinct and distinguishable from other cognitive impairments. Therefore,
it should be taken into account in the classification of MCI subtypes for future research, including
depression as an essential variable in the classification of a patient with cognitive impairment.
Keywords: depression; mild cognitive impairment; MCI; artificial neural network; ANN;
neuropsychological test
1. Introduction
Depression and cognitive impairment are intimately associated, especially in elderly people.
The type of cognitive impairment that has been associated with patients with depression as a group is
mainly dysexecutive and with alteration in speed of information processing and memory function [1,2].
However, there is variability between the cognitive profiles that arise in elderly patients and depression,
Appl. Sci. 2018, 8, 1629; doi:10.3390/app8091629 www.mdpi.com/journal/applsci
Appl. Sci. 2018, 8, 1629 2 of 13
suggesting that this syndrome represents a heterogeneous group of disorders that require careful
treatment planning and close neuropsychiatric monitoring [3].
The relationship between late-life depression (LLD) and mild cognitive impairment (MCI) remains
controversial. Some authors have found depression associated with a subtype of frontal cognitive
impairment in contrast with other amnestic subtypes or an alteration in several domains [4] that mostly
do not progress to dementia [5,6]. Other authors associate depression in MCI as a factor connected with
the possible progression to dementia [7]. According to Panza et al. [8], patients with MCI and a lifetime
history of depression have more than twice the risk of dementia than those without depression. On the
other hand, other authors find that patients with depressive pseudo-dementias are more likely to
develop later a primary degenerative dementia such as Alzheimer’s disease [9].
Broadly, we can say that late-life depression and cognitive impairment can be due to a common
cause, such as a vascular disease, or simply co-exist in time but have different causes, like the depression
that appears in the first stages of Alzheimer’s disease (AD) [3]. Table 1 shows the main clinical features
and the diagnostic criteria for LLD and MCI. It is noteworthy that the profiles are very similar between
both entities.
Table 1. Diagnostic criteria and clinical features in late-life depression (LLD) and mild cognitive
impairment (MCI). CI = cognitive impairment; SD = standard deviation.
Clinical Features LLD MCI
Diagnostic criteria Clinically significant alteration of moodBeginning in the elderly (>50 years)
Clinically significant CI determined by
the presence of alteration of −1.5 SD
below the average in one or more
cognitive areas.
Other symptoms Can present subjective memoryimpairment or MCI
Can or cannot present mood disturbance,
apathy, anxiety, or mild behavioral
impairment
Daily life activities
Can give up doing complex
instrumental activities for motivational
reasons or apathy.
Can present difficulties or have delegated
complex instrumental activities to others
but does not meet criteria for dementia.
Etiology
Psychological factors: motivation, social
isolation, stressors, etc./Biological
factors: alteration of white matter, brain
volume, etc.
Biological factors: vascular small vessel
disease (alteration of white matter), early
signs of Alzheimer’s disease, etc.
Data analysis of MCI or LLD as independent entities has been performed using both classical
statistical and machine learning (ML) methods. A multitude of classification studies exists about the
prediction of an early diagnosis of AD, the differential diagnosis of MCI, and the prediction of its
conversion into AD, as evidenced by the review performed by Sarica et al. [10]. Depression has also
been studied via machine learning methods using clinical and imaging features. For instance, in the
study undertaken by Patel et al. [11], the authors tried to estimate accurate prediction models for LLD
depression diagnosis and treatment response using multiple ML methods with inputs of multi-modal
imaging, clinical, and network-based features. They found that nonlinear combinations of multi-modal
imaging and/or non-imaging measures could successfully estimate prediction models for diagnosis
(87.27% accuracy) and treatment response (89.47% accuracy) of LLD. A recent study proposed an ML
approach to identifying placebo responders in LLD trials [12].
However, the relationship between MCI and LLD has mainly been established using only classical
statistics. In their study, Duffy et al. [13] compared patients with MCI with and without a history of
depression and healthy controls using neuropsychological assessments and ANOVA analysis as well
as the white matter microstructure obtained with diffusion tensor imaging which was analyzed using
tract-based spatial statistics. In addition, to evaluate the association of LLD with MCI and dementia,
Richard et al. [14] used regression methods in their study with the neuropsychological information
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obtained. The study of Liao et al. [15] aimed to examine the characteristics of cognitive dysfunction
in LLD and amnestic MCI with a battery of neuropsychological tests measuring the domains of
memory, executive function, processing speed, attention and visuospatial skill, and neuroimaging
biomarkers using a series of statistical processes including profile analysis and multiple regression
analysis. Only Lebedeva et al. [16], in their study, focused on the prediction of MCI or dementia after
a one-year follow-up in LLD patients using neuropsychological scores and neuroimaging biomarkers,
and employing ML techniques. In that study, MCI and dementia diagnoses were predicted in LLD
patients with an accuracy of 81%.
The analysis of neuropsychological and neuroimaging data with ML techniques has strongly
influenced the neuroscience community. Among the ML techniques, the artificial neural networks
(ANNs) are flexible, non-linear, and multidimensional mathematical systems, easily implemented and
handled, and capable of solving complex functions in very diverse fields [17]. ANNs are computing
paradigms, inspired by neurosciences, where the organization and storage of information are connected
by computational units or nodes to allow signals to travel through the network. ANNs have been
widely used in science, engineering, and medicine for solving different problems. Their ability to
accurately classify and recognize patterns has encouraged researchers to employ them in solving
numerous clinical problems, obtaining remarkable results. In medicine, they have been proposed as
a viable computational tool in order to provide support in clinical decision-making, classification, and
prediction of cognitive functioning [18]. Their clinical applications include diagnosis and outcome
prediction in a wide range of diseases, such as cancer [19], diabetes [20], or acute stroke mortality [21].
Regarding other neurological disorders, ANNs have been recently applied for classifying different
multiple sclerosis courses [22] and for white matter lesion segmentation [23] by using neuroimaging
data. Additionally, they have been used for Parkinson’s disease diagnosis [24] or for epileptic seizure
detection using EEG signals [25,26]. ANNs have also been successfully used in neurodegenerative
diseases for AD prediction [27] or MCI and AD diagnosis using neuropsychological variables [18] or
magnetic resonance neuroimaging biomarkers [28,29].
As we stated before, the mechanisms underpinning the association between depression and MCI
are complex and currently unclear. Therefore, it would be interesting to characterize the common
patterns of cognitive impairment and depression and thus contribute to the understanding of the
potential mechanism involved in the evolution and prognosis of these two diseases. Even though
ML techniques and ANNs have proven very useful in discriminating MCI and AD patients from
healthy controls or LLD patients, there are, to our knowledge, no studies regarding the identification
of MCI associated with depression as an entity. In this study, our primary intent was to explore the
effectiveness of ANNs to identify this MCI associated with depression.
2. Materials and Methods
2.1. Participants
In a retrospective study, an extensive neurological examination was performed in the Neurology
Department of the University Hospital Complex of Santiago de Compostela (http://xxisantiago.sergas.
gal) from January 2016 to December 2017 of patients with suspected MCI. These evaluations were
performed in a standard manner by the same neuropsychologist with expertise in MCI. A patient
was diagnosed with MCI when the individual presented more than one standard deviation below
the age and education norms in well-standardized neuropsychological tests, in several cognitive
areas, or in several indexes within the same area. The exclusion criteria were: (1) patients who in the
cognitive testing did not show evidence of cognitive impairment, (2) patients with a diagnosis of initial
Alzheimer’s disease or other dementias, and (3) patients under 50 years of age.
The MCI patients were classified into two groups: MCI with depression and MCI without
depression. Patients with depression were defined as: those taking antidepressant medication,
under treatment in the Mental Health Department, or having a score above the cut-off point of
Appl. Sci. 2018, 8, 1629 4 of 13
depression established in the Geriatric Depression Scale (GDS). The scale was first created in 1982 by
J.A. Yesavage et al. [30] specifically for identifying depression in the elderly. It has been extensively
used since then and widely tested for reliability and validity. The GDS established a cut-off score of
11 in the elderly, but some authors use a more stringent cut-off score of 14. We used the latter cut-off
because it has proven to be better in elderly people and patients physically ill or with dementia.
2.2. Neuropsychological Evaluation
In this section, the cognitive areas that were evaluated and the tests used for each one
are described:
• Attention. Digit Span Forward and Backward. These tests evaluate the number of digits that
a person can immediately hold in the same direction (attentional span) or in the opposite direction
(working memory). These include the Trail Making Test Part A (TMT A) [31].
• Executive Function. The Frontal Assessment Battery (FAB) [32], a bedside cognitive and behavioral
battery to assess frontal lobe function and identify a dysexecutive syndrome. The Verbal fluency
p and Verbal fluency animals test involves the generation of items from two specific categories
in a minute: words that begin with p and animals. The Spanish multicenter normative studies
(NEURONORMA project) [33] were used.
• Memory. The Spanish adaptation of the California Verbal Learning Test was used, called the Test
of Verbal Learning España-Complutense (TAVEC) [34], where the patient must learn 16 words in
five trials. Then, the patient must learn a new list of interferences. After that, the patient must
remember the first list in short-term free recall, memory with short-term cued recall, long-term
free recall, memory with long-term cued recall, and recognition. The Rey–Osterrieth Complex
Figure Test (Memory) [35] was used to evaluate visual memory; patients had to reproduce the
complex figure they have previously drawn.
• Praxis. The abbreviated Barcelona Test (a-BT) [36], a subtest of gestural and bimanual praxis,
where the patient must make and copy different gestures such as saying hello, asking for silence,
etc., and the visuo-constructional praxis and the Rey–Osterrieth Complex Figure Test (Copy) [35],
where the patient must draw a complex figure.
• Language. The Abbreviated Boston Naming Test (BNT Abbreviated) [37], where the patient must
name 15 drawings, and the abbreviated Barcelona Test (a-BT) command, where the patient must
perform a series of simple commands.
The neuropsychological assessment was standardized according to age and education norms for
the Spanish population, and z-scores were calculated for the 17 tests.
2.3. Statistical Analysis
The Statistical Package for Social Sciences (SPSS v.22) was used to investigate group differences in
neuropsychological z-scores. The analysis of variance (ANOVA) with post hoc analysis (Bonferroni)
was used to compare neuropsychological data amongst groups (significance level was set at 0.001).
The homogeneity of variance assumption was met for all variables (Levene test).
2.4. Classification Using Artificial Neural Networks
A multi-layer perceptron neural network (MLPNN) was used for the analysis. The MLPNN is
a neural network for performing varied detection and classification tasks. MLPNN has features such
as the ability to learn and generalize, a smaller training data requirement, fast operation, and easy
implementation. For these reasons, it is one of the neural network models most widely used [25].
It organizes the processing units, neurons, in layers with feedforward connections only between
consecutive layers. Therefore, the general scheme includes an input layer, zero or more hidden
layers, and an output layer (see Figure 1). The MLPNN training process was performed using
a back-propagation technique in a supervised learning scheme. For the neural transfer functions,
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a hyperbolic tangent sigmoid function for the hidden layers and a normalized exponential function
for the output layer were used. The following approach was applied for the optimization of the
MLPNN performance:
• Data partition. Data partitioning can be used to determine the accuracy of a model’s estimates of
new data. For this work, we chose a 10-fold repeated cross-validation method. This subtype of
cross-validation method randomly breaks the dataset into 10 subsets, which are sequentially used
as test sets, while the other nine are used for training. This cross-validation method was repeated
50 times to obtain the information necessary to perform a statistically significant evaluation.
• Architecture selection. The number of neurons, layers, and their connections determine the
architecture of an ANN. There is no general rule in choosing the best architecture, and optimization
is based on testing several architectures until finding one that might offer satisfactory results [25].
Several architectures of the ANN with one and two hidden layers were tested to choose the
best one. We evaluated architectures of 3, 8, 12, and 15 neurons for one-layer examples and
architectures of {5 3}, {8 5}, {10 8}, and {12 10} neurons for two-layer examples. The optimization
algorithm used to train these ANNs is a variation of the gradient descent known as scaled
conjugate gradient backpropagation [38]. The results were compared using an analysis of variance
(ANOVA) and Tukey’s honest significance test [39], and a p-value of <0.01 was used to determine
whether there were statistically significant differences between the proposed architectures.
• Cut-off value selection. For a given cut-off value or decision threshold, each patient was classified
in one of the diagnostic groups by comparing the measurement to this cut-off value. Choosing
an appropriate decision threshold is of paramount importance in using a test effectively. There
are various methods to determine the optimal test cut-off value, mostly based on a receiver
operating characteristic (ROC) analysis. The ROC curve offers a graphical illustration of the true
positive rate (sensitivity) against the false positive rate (1–specificity) for all possible cut-off values.
Thus, each point on an ROC curve corresponds to a cut-off value and is associated with a test
sensitivity and specificity. Sensitivity is the number of correctly detected positive patterns/total
number of actual positive patterns. A positive pattern in this context indicates an MCI patient
with depression. On the other hand, specificity is the number of correctly detected negative
patterns/total number of actual negative patterns. A negative pattern in this context indicates an
MCI patient without depression. Locating the best cut-off point requires a compromise between
both measures. One of the most common criteria, and the one chosen in this work, is the point
on an ROC curve with the best trade-off between specificity and sensitivity, trying to maximize
both indices.
• Performance analysis. The following statistical parameters were computed to evaluate the
MLPNN classification performance:
◦ Accuracy: Number of correctly classified patterns/total number of patterns.
◦ Sensitivity: The MLPNN’s ability to correctly detect MCI patients with depression.
◦ Specificity: The MLPNN’s ability to correctly detect MCI patients without depression.
◦ AUC: Area under an ROC curve, one of the most important evaluation metrics for any
classification model’s performance.
This procedure was applied to two ANN substudies: (1) using the whole sample of
17 neuropsychological tests as input patterns and (2) instead of using all features, using the results of
the ANOVA analysis to identify the most relevant features. Thus, this substudy contained a subset of
the 17 neuropsychological features, that is, those features showing significant differences and, therefore,
better able to distinguish between both groups. The objective of the second substudy was to evaluate
whether those features could distinguish groups more effectively and whether they could improve the
prediction performance with respect to the entire sample.
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3. Results
From the initial sample of 162 subjects, 27 were excluded because the cognitive testing did not
show evidence of cognitive impairment. Furthermore, 30 patients were excluded because of a diagnosis
of initial Alzheimer’s disease or other dementias and 9 patients, for being under 50 years of age.
The remaining 96 patients were classified into two MCI groups: MCI with depression (N = 42, mean
age 65.7 years, range 52–76) and MCI without depression (N = 54, mean age 69.6 years, range 56–79).
Table 2 summarizes the results from the neuropsychological evaluation of the two groups,
MCI with depression and MCI without depression. These results showed a mainly frontal deterioration
profile, with mean scores of two standard deviations below the average in the frontal test (FAB), and
a low result, that approached one standard deviation below the average, in memory tests. Significant
group differences in the ANOVA analysis were found between groups for the Verbal Learning Test
(TAVEC) and the Rey complex figure test. Compared to patients without depression, patients with
depression had a better performance in all tasks related with verbal memory, but particularly, they had
an improvement in memory tasks with cued recall compared with those of free recall. This pattern
was not found in patients without depression. In addition, patients with depression showed a worse
performance in the copy of the Rey complex figure.
For this work, two substudies of ANNs were carried out in order to identify MCI associated with
depression. Table 3 shows the results obtained in both substudies for all the evaluated architectures.
Substudy 1 used the z-scores as inputs for the 17 neuropsychological tests. For substudy 2, a subset of
features was chosen, namely those tests with more significant differences from Table 2. These were
as follows: the Digit Span Backward, the copy of the Rey complex figure and the six subsets of the
TAVEC test (8 inputs in total).
Hypothesis tests should be performed to check the significance of differences between ANN
configurations [40]. Table 3 shows that statistically significant differences were observed between
different architectures. To decide between architectures having statistically equal performances, it is
preferred to choose the less complex architecture with the higher accuracy, because simpler models
tend to be less prone to overfitting. Therefore, among the evaluated architectures, the one with the best
performance with the test dataset was a single hidden layer architecture consisting of 15 neurons for
substudy 1 with an accuracy of 86% (sensitivity = 82%, specificity = 89%, AUC = 0.95), which indicated
an excellent classification performance. The specificity reached 89%, which meant that the 89% of MCI
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patients without depression were correctly classified. The sensitivity parameter showed that the 82%
of MCI patients with depression were correctly identified by the MLPNN.
Table 2. Neuropsychological z-scores for the two groups studied: MCI with depression and MCI
without depression. Data are presented in the following form: mean ± standard deviation. Group
differences were performed by analysis of variance (ANOVA) with post hoc analysis (Bonferroni), and
the significance level was set at 0.001. The degrees of freedom for F values are (1, 95). MCI = mild
cognitive impairment; TMT = Trail Making Test; FAB = Frontal Assessment Battery; TAVEC = Test of
Verbal Learning España-Complutense; Rey–OCF = Rey–Osterrieth Complex Figure; a-BT = abbreviated
Barcelona test.
Variables MCI withDepression
MCI without
Depression F p Value
Digit Span Forward 0.20 ± 0.89 0.16 ± 0.74 0.04 0.845
Digit Span Backward −0.10 ± 0.96 0.53 ± 0.63 9.26 0.004
TMT A −0.48 ± 1.05 −0.31 ± 0.82 0.49 0.484
FAB −1.95 ± 1.99 −2.35 ± 1.71 0.67 0.416
Verbal fluency P −0.51 ± 0.66 −0.49 ± 0.73 0.01 0.945
Verbal fluency animals −0.81 ± 0.85 −1.06 ± 0.72 1.41 0.240
TAVEC immediate memory −0.84 ± 1.05 −1.67 ± 0.62 14.31 <0.001
TAVEC short-term free recall −0.77 ± 1.07 −1.81 ± 1.07 13.25 <0.001
TAVEC memory (short-term cued recall) −0.48 ± 0.93 −1.71 ± 0.96 23.22 <0.001
TAVEC long-term free recall −0.86 ± 1.02 −2.10 ± 1.00 21.10 <0.001
TAVEC memory (long-term cued recall) −0.65 ± 1.02 −2.14 ± 0.96 31.70 <0.001
TAVEC recognition −0.57 ± 0.96 −1.33 ± 1.12 7.07 0.010
Rey–OCF (memory) −0.58 ± 0.93 −0.63 ± 0.88 0.04 0.838
Rey–OCF (copy) −0.52 ± 0.76 −0.08 ± 0.51 7.11 0.010
a-BT praxis −0.69 ± 2.22 −0.60 ± 1.96 0.029 0.865
a-BT praxis bimanual −0.57 ± 2.11 −0.67 ± 3.04 0.02 0.900
a-BT command −0.32 ± 1.25 −0.05 ± 0.84 0.97 0.329
From the results shown in Table 3, the following can be observed. In general, the architectures
with a single hidden layer perform better than the two-layer architectures. In general, the specificity
results are higher than the sensitivity results for all the evaluated architectures in both substudies.
Substudy 2 also obtains a good performance (accuracies over 69%) for all the architectures, but only the
architecture with two hidden layers of 5 and 3 neurons respectively improves the results of substudy 1
(accuracy = 80%, sensitivity = 73%, specificity = 84%, AUC = 0.93).
The main objective of substudy 2 was to reduce the number of original features by selecting
a subset of them and evaluating whether they still retained sufficient information for classification.
According to the ANOVA theory, for smaller values of significance, the discriminative capability is
better. However, our results showed that, although the subset of eight neuropsychological tests was
the one with greater differences between groups, they did not improve the prediction performance
with respect to the entire sample. The 17 features were necessary to attain maximum performance.
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Table 3. Results of the evaluated architectures for the multi-layer perceptron neural network (MLPNN) analysis with the test data. Data are presented in the following
form: mean ± standard deviation. Means in a column with no common superscript letter differ significantly according to Tukey’s honest significance test for a value of
p < 0.01. Substudy 1 has 17 neurons in the input layer (all the neuropsychological tests) and substudy 2 has eight neurons in the input layer (test with more significant
differences from Table 2: the Digit Span Backward, the copy of the Rey complex figure and the six subsets of the TAVEC test). The best results for each substudy are in
bold. Net. Archit. = Network Architecture.
Net. Archit.
Accuracy Sensitivity Specificity AUC
Substudy 1 Substudy 2 Substudy 1 Substudy 2 Substudy 1 Substudy 2 Substudy 1 Substudy 2
{3} 0.75 ac ± 0.17 0.69 ac ± 0.11 0.72 ac ± 0.31 0.77 a ± 0.24 0.88 a ± 0.20 0.74 abc ± 0.19 0.93 a ± 0.07 0.89 a ± 0.10
{8} 0.78 ac ± 0.18 0.79 bc ± 0.15 0.69 ac ± 0.31 0.80 a ± 0.26 0.85 a ± 0.27 0.79 abd ± 0.24 0.94 a ± 0.04 0.92 a ± 0.08
{12} 0.78 ac ± 0.20 0.73 ac ± 0.17 0.76 ac ± 0.21 0.75 a ± 0.33 0.80 a ± 0.32 0.78 abd ± 0.21 0.94 a ± 0.06 0.91 a ± 0.07
{15} 0.86 b ± 0.19 0.74 ac ± 0.08 0.82 b ± 0.32 0.79 a ± 0.32 0.89 a± 0.17 0.68 ac ± 0.26 0.95 a ± 0.05 0.90 a ± 0.06
{5 3} 0.76 ac ± 0.16 0.80 b ± 0.12 0.88 bc ± 0.21 0.73 ab ± 0.25 0.69 b ± 0.27 0.84 bd ± 0.21 0.93 a ± 0.04 0.93 a ± 0.07
{8 5} 0.71 c ± 0.22 0.71 ac ± 0.16 0.76 ac ±0.31 0.75 a ± 0.29 0.67 b ± 0.33 0.68 ac ± 0.25 0.92 a ± 0.07 0.90 a ± 0.04
{10 8} 0.76 ac ± 0.19 0.70 ac ± 0.20 0.68 ac ± 0.39 0.68 ab ± 0.32 0.78 a ± 0.22 0.66 ac ± 0.34 0.92 a ± 0.04 0.90 a ± 0.10
{12 10} 0.79 b ± 0.15 0.71 ac ± 0.22 0.83 bc ± 0.18 0.62 b ± 0.38 0.83 a ± 0.19 0.86 bd ± 0.16 0.92 a ± 0.09 0.90 a ± 0.08
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4. Discussion
The purpose of this study was to explore the effectiveness of ANNs to identify an MCI diagnosis
associated with depression. According to our results, the ANN allowed distinguishing between MCI
patients with and without depression with an accuracy of 86% (sensitivity = 82%, specificity = 89%,
AUC = 0.95). Those results were based on the application, for the first time, of ANNs to identify
an MCI subtype associated with depression. Therefore, it is difficult to compare our results with
previous studies. A similar study [16], although it used an inverse approach, tried to discriminate
between LLD patients who were diagnosed with MCI or dementia using a random forest classifier
and neuroimaging biomarkers. The authors predicted MCI and dementia diagnoses in LLD patients
with an accuracy of 81% (sensitivity = 75% and specificity = 86%). We reached a superior classification
performance in our study.
Sensitivity and specificity results demonstrated that ANNs performed better in identifying MCI
patients non-associated with depression than in MCI patients associated with depression. The reason
that might explain these results was the heterogeneity in the depression group, where there could be
patients with LLD and, theoretically, the depression would be one more symptom of vascular damage
and there could be patients who had cognitive impairment and depression but due to a different
profile or cause. The group with depression had a higher variability due to the symptom spectrum
of cognitive impairments. This study highlights the value of neuropsychological data, a relatively
inexpensive and non-invasive technique required for diagnosis purposes whose predictive power has
not been fully exploited, as it has been addressed mostly by classical statistical methods.
From a cognitive point of view, the results showed a below-average performance in memory tasks
in both groups, worse in those patients without depression. Performance improved slightly with the
use of cues in depressed patients. Other studies [41,42] found a similar memory profile in patients
with depression, characterized by difficulties in the recovery processes that were more influenced
by executive functions such as free recall, as opposed to other recovery processes using cues and
recognition. The fact that patients with depression score better in memory tests supports the idea
that, in the group of patients complaining of memory problems and who are not depressed, there
are more patients in a prodromal phase of Alzheimer’s disease and that, in the group of patients
with cognitive impairment and depression, there are more patients with a small vessel disease as the
origin (that disease affects the executive functions more than memory, because it affects connection
areas and frontal lobes more than structures such as the hippocampus, which are affected early in
Alzheimer’s disease).
In addition, a worse performance was found in the Rey complex figure for patients with
depression. This test evaluates visuo-constructional praxis, but also executive functions. A recent
study [43] shows that patients with vascular MCI scored worse than patients with MCI associated
with a degenerative cause.
Although this study did not consider a qualitative evaluation, the quantitative assessment showed
a deficit that could be the cause of this executive dysfunction, since patients with depression did show
a very similar or even better performance in the copy of the figure than in memory (the patients with
depression did show a worse performance in the copy of the figure). On the contrary, the group
without depression performed worse in memory tasks than in the copy. This would be in favor of
an equally dysexecutive profile of these patients as it appears in the literature. In the specifically frontal
test, the FAB, patients with depression obtained an average affectation of two standard deviations
below their normative group.
This dysexecutive profile supports the hypothesis of many authors regarding the existence of
a “vascular depression” characterized by its appearance in advanced ages, the presence of vascular
lesions in neuroimaging tests, vascular risk factors, and a poor response to antidepressants [44]. It has
been argued that patients with this profile have abnormalities in the frontal lobes and their connections
with the limbic and striatal system [44]. Studies with functional magnetic resonance using the default
mode network and functional connectivity techniques have observed an altered connection between
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areas of the dorsolateral, dorsal, and rostral prefrontal cortex with regions of the anterior part of the
cingulum, and areas of association [45,46]. The Framingham Heart Study [47] found that the white
matter integrity (WMI) was positively associated with change in depression symptoms and that those
with an extensive WMI at baseline had a high risk of developing severe depression, in the absence of
cardiovascular diseases.
This type of analysis helps us to see the importance of depression in the classification of patients
with mild cognitive impairment. As Petersen et al. indicate [48], the concept of MCI is evolving, and
the classical classification systems in amnestic MCI and non-amnestic MCI are being improved by the
incorporation of new data as the biomarkers. This improvement allows a better classification of those
patients with MCI who are in a prodromal phase of Alzheimer’s disease [49]. However, the depression
in the new classification systems continues to be shown to be independent of the MCI, either as a cause
in major depression or as an independent added symptom when it is milder [50]. However, in our
study, we were able to distinguish between depressive and non-depressed patients only with cognitive
data. Thus, we showed how depression could be a further alteration of the process underlying the
MCI, forming with it a possible subtype of MCI. It would therefore be interesting to include depression
as part of that MCI, and not as something external to it.
However, this study should be interpreted within the context of several limitations. First,
the sample size was relatively small. Because this was a retrospective study, we had to deal with
missing variables that were not collected at the time and, due to that, many patients could not be
included in the ANN analysis. For example, data concerning the antidepressant treatments or their
effect were not collected. Although one of the characteristics of LLD patients as a group is the
poor response to treatment, it is true that at the individual level it can have an effect, especially in
those patients who present MCI and associated reactive depression. Therefore, future studies should
consider this variable to evaluate its impact on the results. In addition, this study only included
neuropsychological scores. Future work should focus on incorporating other variables of interest,
such as the presence of vascular risk factors and neuroimaging data, and on performing extensive
studies for comparing the efficiency of this model with other non-linear methods, such as non-linear
discriminant analysis or support vector machines. Despite the limitations, this study shows that ANNs
are a useful tool for studying this pathology. They provide data in favor of a cognitive frontal profile
of patients with LLD, distinct and distinguishable from other cognitive impairments, regardless of the
assessment made about their mood.
5. Conclusions
Until now, the classification of MCI subtypes has been based on the presence of memory
impairment or deficits in multiple cognitive domains due to the influence of the profile classically
associated with Alzheimer’s disease. Our study shows that ANNs can identify a cognitive impairment
that affects free recall memory and the executive functions, but mostly, one that is highly associated
with depression. This MCI associated with depression as an entity is distinguishable from the rest
of MCI. Therefore, it should be taken into account in the classification of MCI subtypes for future
research, including depression as an essential variable in the classification of a patient with cognitive
impairment. However, new studies are needed in this regard and the analysis of ANNs has proven to
be an adequate tool for that research.
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